|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | The pharmacokinetics and pharmaeodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction显示文摘 | Swan SK Hursting MJ | 2000 | Pharmacotherapy2000，20，： | 1 |
| 2 | The pharmacokinetics of a single oral dose of mycophenolate mofetil in patients with varying degrees of renal function显示文摘 | Johnson I-IJ Swan SK Heim-Duthoy KL | 1998 | Clin Pharmacol Ther1998，63，5： | 1 |
| 3 | Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects显示文摘 | Swan SK St Peter JV Lambrecht LJ | 2000 | Pharmacotherapy2000，20，： | 1 |
| 4 | The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction显示文摘 | Swan SK Hursting MJ | 2000 | Pharmacotherapy2000，20，： | 1 |
| 5 | The search continues-an ideal marker of GFR显示文摘 | Swan SK | 1997 | Clin Chem1997，43，： | 1 |
| 6 | Aminoglycoside nephrotoxicity 显示文摘 | Swan SK | 1997 | Semin Nephrol1997，17，： | 1 |
| 7 | The search continues an ideal marker for GFR显示文摘 | Swan SK | 1997 | Clin Chen1997，43，： | 1 |
| 8 | Review article∶ the pharmacokinetics ofrabeprazole in health and disease显示文摘 | Swan SK Hoyumpa AM Merritt GJ | 1999 | Aliment Pharmacol Ther1999，13，3： | 1 |
| 9 | Cyclooxygenase-2 and atherosclerosis: friendor foe? 显示文摘 | Massy ZA Swan SK | 2001 | Nephrol Dial Transplant2001，16，12： | 1 |
| 10 | Disposition of recombinant human interleukin-10 in subjects with various degrees of renal function显示文摘 | Lambrecht LJ Swan SK | 1999 | J Clin Pharmacol1999，39，10： | 1 |
| 11 | Tegaserod pharmacokinetics are similar in patients with severe renal insufficiency and in healthy subjets显示文摘 | Swan SK Zhou H Horowitz A | 2003 | J of Clin Pharmacol2003，43，4： | 1 |
| 12 | The pharmacokinetics and pharmacodynamicsof ai^atroban:effects of age,gender,and hepatic or renal dysfunction显示文摘 | Swan SK Hursting MJ | 2000 | Phamiacotherapy2000，20，3： | 1 |
| 13 | Review article: the pharmacokinetics of rabeprazole in health and disease 显示文摘 | SWAN SK HOYUMPA AM MERRITT GJ | 1999 | Aliment Pharmacol Ther1999，13，3： | 1 |
| 14 | Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects显示文摘 | Swan SK St Peter JV Lambrecht LJ | 2000 | Pharmacotherapy2000，20，7： | 1 |
| 15 | The pharmacokinetics and pharmaeodynamics of argatroban:effects of age,gender,and hepatic or renaldysfunction显示文摘 | Swan SK Hursting M J | | 0，，： | 1 |
| 16 | The pharmacokinetics and pharmacodynamics of argatroban:Effects of age,gender,and hepatic or renal dysfunction显示文摘 | Swan SK Hursting MJ | 2000 | Pharmacotherapy2000，20，3： | 1 |
| 17 | Comparison ofanticoagulant effects and safety of argatroban and heparin inhealthy subjects显示文摘 | Swan SK St Peter JV Lambrecht LJ | 2000 | Pharmacotherapy2000，20，7： | 1 |
| 18 | A mutation in the 5'-UTR of IFITM5 creates an in-frame start codon and causes autosomal-dominant osteo-genesis imperfecta type V with hyperplastic callus显示文摘 | Semler O Garbes L Keupp K Swan D Zimmermann K Becker J Iden S Wirth B Eysel P Koerber F Schoenau E Bohlander SK Wollnik B Netzer C | | 0，，： | 1 |
| 19 | The pharmacokinetics and pharmacody- namicsof argatroban:effects of age,gender,and hepatic or renal dysfunction显示文摘 | Swan SK Hursting MJ | 2000 | Pharmacotherapy2000，20，3： | 1 |
| 20 | Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet显示文摘 | Rudy DW Lasseter KC | 2000 | Ann Intern Med2000，133，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员